Is AKRO or JNJ a better dividend investment in 2026?

AKRO currently yields 3.66% with a 5% 5-year dividend growth rate. JNJ yields 3.36% with 5.8% growth. The better choice depends on your goal: AKRO offers higher current income.

What is the dividend yield difference between AKRO and JNJ?

AKRO has a forward dividend yield of 3.66% ($2.00/share annually). JNJ yields 3.36% ($4.96/share annually). The yield gap is 0.30 percentage points.

Home › Compare › AKRO vs JNJ

AKRO vs JNJ: Dividend Comparison 2026

AKRO yields 3.66% · JNJ yields 3.36%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 AKRO wins by $5.3K in total portfolio value

INVESTMENT

TIME HORIZON10 years

AKRO

● Live price

3.66%

Share price

$54.65

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$463.02

Full AKRO calculator →

JNJ

Johnson & Johnson

● Live price

3.36%

Share price

$147.50

Annual div

$4.96

5Y div CAGR

5.8%

Payout ratio

55%

After 10 yrs · $10,000 · DRIP

Portfolio value

$20.0K

Annual income

$827.78

Full JNJ calculator →

Portfolio growth — AKRO vs JNJ

📍 AKRO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	AKRO	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, AKRO + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

AKRO pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AKRO

Annual income on $10K today (after 15% tax)

$311.07/yr

After 10yr DRIP, annual income (after tax)

$393.57/yr

JNJ

Annual income on $10K today (after 15% tax)

$285.83/yr

After 10yr DRIP, annual income (after tax)

$703.61/yr

At 15% tax rate, JNJ beats the other by $310.05/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AKRO + JNJ for your $10,000?

AKRO: 50%JNJ: 50%

100% JNJ50/50100% AKRO

Portfolio after 10yr

$22.7K

Annual income

$645.40/yr

Blended yield

2.84%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AKRO

Analyst Ratings

Buy

Hold

Consensus: Buy

Price Target

$54.67

+0.0% upside vs current

Range: $54.00 — $56.00

Altman Z

54.7

Piotroski

2/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

+55.1% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AKRO buys

JNJ buys

No recent congressional trades found for AKRO or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricAKROJNJ

Forward yield	3.66% ✓	3.36%
Annual dividend / share	$2.00	$4.96 ✓
Payout ratio	50% ✓	55%
1-year div growth	0%	4.2% ✓
5-year div CAGR	0%	5.8% ✓
Portfolio after 10y	$25.4K ✓	$20.0K
Annual income after 10y	$463.02	$827.78 ✓
Total dividends collected	$4.2K	$5.6K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare
Analyst consensus	Buy	Buy
Analyst price target	$54.67	$228.73 ✓

Year-by-year: AKRO vs JNJ ($10,000, DRIP)

Year	AKRO Portfolio	AKRO Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$11,066	$365.97	$10,676	$355.77	+$390.00 → AKRO
2	$12,219	$378.48	$11,407	$389.39	+$812.00 → AKRO
3	$13,465	$390.58	$12,198	$426.53	+$1.3K → AKRO
4	$14,810	$402.25	$13,056	$467.62	+$1.8K → AKRO
5	$16,260	$413.48	$13,987	$513.12	+$2.3K → AKRO
6	$17,822	$424.27	$14,998	$563.56	+$2.8K → AKRO
7	$19,505	$434.61	$16,098	$619.52	+$3.4K → AKRO
8	$21,314	$444.52	$17,295	$681.69	+$4.0K → AKRO
9	$23,260	$453.99	$18,599	$750.82	+$4.7K → AKRO
10	$25,352	$463.02	$20,022	$827.78	+$5.3K → AKRO

AKRO vs JNJ: Complete Analysis 2026

AKRO — Stock

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Full AKRO Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →

📬

Get this AKRO vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AKRO vs SCHD AKRO vs JEPI AKRO vs O AKRO vs KO AKRO vs MAIN AKRO vs ABBV AKRO vs MRK AKRO vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.